Novo Nordisk: Demand drives another equipment boost in Clayton, US

By Flora Southey contact

- Last updated on GMT


Related tags: Insulin

Novo Nordisk is planning a $65m (€53m) production capacity expansion at its finished product site in North Carolina, to meet demand for diabetes and obesity medicines.

The Danish firm said it will “acquire additional operational equipment” ​at the Diabetes Finished Product (DFP) facility in Clayton to respond to growing demand for drug products.

The existing facility – located on a 264-acre campus in Johnston County – offers enough open space to house the additional equipment, spokesperson Erin O’Brien told us.

The site is responsible for making, filling and packaging diabetes and obesity products such as liraglutide, as well as assembling prefilled insulin devices for the US market.

Novo Nordisk predicts the project will be completed in Q4, 2019, and the site fully operational in 2020.

The expansion “is likely to create at least two dozen additional positions” ​from 2020 onwards, we were told.

“These positions include operators and technicians, as well as professional engineers and quality personnel,” ​said O’Brien.

The firm continues to assess plans for future expansions at the Clayton site.

We have “not reached a final decision at this time on whether we will move forward with any further initiatives,” ​O’Brien told us.

Novo Nordisk has expanded its Clayton campus several times since it launched in 1993.

In 2015, the drugmaker announced​ plans to spend $2bn constructing diabetes active pharmaceutical ingredients (API) and production plants in Clayton, US and Måløv, Denmark.  

Related news

Related products

show more

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

Single-Pass Tangential Flow Filtration

Single-Pass Tangential Flow Filtration

BioContinuum™ Platform - MilliporeSigma | 01-Aug-2020 | Application Note

Tangential flow filtration (TFF) is widely used in the biopharmaceutical industry for downstream processing applications. Typical TFF steps concentrate...

Follow us


View more